Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders. In September 2008, the Company entered into a lease for laboratory space for a small scale research facility in San Diego, Calif. This facility will complement Amicus' core research and development activities in New Jersey, while allowing closer access to the significant scientific and biotechnology resources in the San Diego community.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended September 30, 2008, was $8.2 million as compared to $10.3 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended September 30, 2008, was $6.6 million as compared to $9.2 million in the same period in 2007.

Amicus recorded revenue during the third quarter of 20
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... , , , , ... A New Tool for the Rapid and Efficient Extraction,from Swabs in Research Samples , ... , Swabs are commonly used for sample extraction from a,variety ... procedure, the infectious agents are typically,released into a culture medium or onto a culture plate. ...
... , , ... , Transcriptor Reverse Transcriptase is a new recombinant,reverse ... DNA polymerase activity, unwinding,activity, and, importantly, RNase H activity. , ... , Due to the special recombinant structure of ...
... , , ... , Protector RNase Inhibitor ... of,RNases. , Does not interfere with the performance of enzymes in an ... Inhibitor are needed to protect difficult RNA samples. , Is fully active ...
Cached Biology Technology:S.E.T.S. Swab Extraction Tube System 2Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 2Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 3Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 4Protector RNase Inhibitor Enhance the Protection of,RNA against Degradation 2
(Date:8/28/2014)... German . ... the help of sophisticated assembly lines. Mobile assembly carriers, on ... of these assembly lines. In the case of a car ... arranged in a precise spatial and chronological sequence, resulting in ... The creation of such an assembly line at molecular level ...
(Date:8/28/2014)... from Washington, Oregon, northern California, and Alaska totaled 515 ... of 2014, an increase of more than 10 percent ... Forest Service,s Pacific Northwest Research Station reported today. During ... 4 percent to 247 million board feet. , The ... than 5 percent to $390 million in the same ...
(Date:8/28/2014)... countries will be fully saturated with pests by the ... to a new study led by the University of ... be found in around half the countries that grow ... current rate, scientists fear that a significant proportion of ... the next 30 years. , Crop pests include fungi, ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3West coast log exports up, lumber exports down in second quarter of 2014 2New study charts the global invasion of crop pests 2
... influenza (H5N1), rabies, plague, Bovine Spongiform Encephalopathy (BSE), and ... diseases that have made the leap from animals to ... The University of Nottingham are to lead a project ... monitor emerging and re-emerging infections in wildlife. Sixty ...
... degradation in dryland regions continuing to worsen, the ... scientist-recommended indicators for monitoring and assessing desertification that ... agreement was reached after two weeks of negotiations ... the Ninth Session of the Conference of the ...
... science and technology university has formed a tripartite ... Research (Centre National de la Recherche Scientifique or ... and Thales the French electronics giant and a ... and transportation industries. The alliance known as ...
Cached Biology News:Protecting humans and animals from diseases in wildlife 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3New Singapore-France research alliance to develop state-of-the-art nanotechnologies 2New Singapore-France research alliance to develop state-of-the-art nanotechnologies 3
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
Biology Products: